A5031767514- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- HER2/EGFR in Cancer Research
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Cancer Immunotherapy and Biomarkers
- Breast Lesions and Carcinomas
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Screening and Detection
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Breast Cancer Therapies
- Cancer-related Molecular Pathways
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Economic and Financial Impacts of Cancer
- Peptidase Inhibition and Analysis
- Pharmacy and Medical Practices
- Digital Rights Management and Security
Institut Jules Bordet
2019-2025
Ospedale Policlinico San Martino
2015-2024
Université Libre de Bruxelles
2019-2024
International Drug Development Institute (Belgium)
2022
Fondazione IRCCS Istituto Nazionale dei Tumori
2014-2017
Azienda Ospedaliera Treviglio
2017
Azienda Socio Sanitaria Territoriale di Bergamo Ovest
2017
This Viewpoint questions a recently published treatment algorithm for patients with HER2-amplified metastatic colorectal cancer and proposes alternative timing HER2 testing HER2-directed therapies.
Obesity is a known risk factor for breast cancer and has been linked to increased of recurrence death in patients. Little about the predictive value obesity. As endocrine therapy widely used treatment worldwide, we aimed at correlating baseline body mass index (BMI) with clinical benefit derived from fulvestrant postmenopausal women advanced cancer.We analyzed consecutive patients treated our center between January 2009 March 2015. Patients were categorized as normal (BMI 18.5-24.9 kg/m2),...
The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal cancer is imperative. aim of this study was investigate the prognostic role circulating VEGF, PDGF, SDF-1, osteopontin and CEA patients randomly assigned three regimens. Plasma samples from 50 treated at a single Institution were analysed using multiplex assay BioPlex™ 2200 (Bio-Rad Laboratories, Inc, Berkeley, CA, USA) baseline, before first cycles subsequently every until disease progression. Prognostic...
Neuroendocrine carcinoma is an uncommon histology for breast cancer.Our patient underwent right quadrantectomy a neuroendocrine in 1984 and had bone relapse 30 years later. After thorough pathological immunohistochemical analysis the diagnosis was confirmed HER2 amplification observed. Here we discuss management, rationale results of HER2-targeted therapy advanced carcinoma.
The aim of this study was to perform a quantitative quality assurance diffusion-weighted MRI assess the variability mean apparent diffusion coefficient (ADC) and other radiomic features across scanners involved in REGINA trial.The NIST/QIBA phantom acquired on six 3 T from five centres with rectum-specific protocol. All sequences were repeated each scan session without moving table. Linear interpolation two isotropic voxel spacing (0.9 4 mm) performed as well ComBat feature harmonisation...
Potential intrinsic resistance mechanisms to regorafenib were explored after short exposure (3 days) on five CRC cell lines (HCT-116, SW1116, LS-1034, SW480, Caco-2). The observation of senescence-like features led the investigation a drug-initiated phenotype switch. Following long-term (12 months) HCT-116 and SW480 regorafenib, we developed resistant models explore acquired resistance. cells demonstrated senescent-like properties, including arrest in late G2/prophase cycle stage...
<b><i>Background:</i></b> Breast cancer (BC) phenotype after neoadjuvant chemotherapy (NAC) has not been extensively described and few data exist on whether expression of the primary tumor hormone receptors, HER2 Ki-67 changes as a result chemotherapy. <b><i>Materials Methods:</i></b> We analyzed specimens from all BC patients treated with anthracycline/taxane-based NAC at our Institution between January 2010 March 2015 (n = 325). The estrogen...
Abstract Background Although American Society of Clinical Oncology and European for Medical guidelines have identified the negative prognostic factors that clinicians to consider when treating their patients with stage II colon cancer (CC), role histological subtype is controversial. Subjects, Materials, Methods The randomized, multicenter, phase III TOSCA trial compared 3 versus 6 months fluoropyrimidine-oxaliplatin adjuvant chemotherapy in 3,759 high-risk or CC. objective this substudy was...